187164-19-8 Categories: , , ,
  • # LGM Pharma is a Luliconazole CAS# 187164-19-8 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Luliconazole
  • CAS #: 187164-19-8
  • Mode of Action:

    The exact mechanism of action for luliconazole's anti-fungal activity is still not known, but luliconazole is thought to inhibit the enzyme lanosterol demethylase. Lanosterol demethylase is needed for the synthesis of ergosterol, which is a major component of the fungus cell membranes.

  • Pharmacodynamics:

    Luliconazole kills the organisms Trichophyton rubrum and Epidermophyton floccosum, most likely by altering their fungal cell membranes.

  • Metabolism:

    The metabolism of luliconazole has yet to be determined.

  • Toxicity:

    In clinical trials, no serious toxicity was reported, only local irritation (mild contact dermatitis and cellulitis) at the site of application was found.

  • IUPAC: 2-[(2E)-4-(2, 4-dichlorophenyl)-1, 3-dithiolan-2-ylidene]-2-(1H-imidazol-1-yl)acetonitrile
  • ATC: D01AC18
  • PubChem: 9863407
  • DrugBank: DB08933
  • Formula: C14-H9-Cl2-N3-S2
  • Molecular Mass: 354.2841
  • Synonyms: (-)-(E)-((4R)-4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene)(1H-imidazol-1-yl)acetonitrile, Luliconazole, Luzu, NND 502, NND-502, NND502, PR-2699, UNII-RE91AN4S8G
  • SMILES: c1cc(c(cc1Cl)Cl)[C@@H]2CS/C(=C(/C#N)3ccnc3)/S2
  • InChl: 1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1
  • General Reference:


    1. Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H: In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother. 1998 Apr;42(4):967-70. Pubmed
    2. Uchida K, Nishiyama Y, Yamaguchi H: In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother. 2004 Aug;10(4):216-9. Pubmed
    3. Lexicomp.
    4. FDA label.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements
This website uses cookies. By using our site, you agree to our terms of service